# Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

> **NCT07650942** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ganzhou Hemay Pharmaceutical Co., Ltd** · enrollment: 360 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Hemay005 tablet
- **DRUG:** Placebo
- **DRUG:** Hemay005 tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07650942
- **Lead sponsor:** Ganzhou Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-05
- **Final completion:** 2029-02
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650942, "Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*